Expert review of anticancer therapy
-
Introduction: Fibroblast growth-factor receptor (FGFR) inhibition is a promising strategy of treatment in urothelial cancer (UC). FGFR3 mutations or fusions (mut/fus) are common in luminal-1 UC subtype, which exhibits poor responses to immunotherapy. Erdafitinib is a potent and selective pan-FGFR tyrosine kinase inhibitor. ⋯ Special attention must be paid to typical adverse class-effects of FGFR inhibitors. In the near future, in order to achieve an optimal selection of molecularly-altered tumors, it will be important to assess the performance of different diagnostic tools and to investigate the role of liquid biopsy. Combinations with immunotherapy represent a novel therapeutic opportunity being tested in ongoing trials.
-
Expert Rev Anticancer Ther · Aug 2019
ReviewCapmatinib for the treatment of non-small cell lung cancer.
Introduction: Activation of the MET pathway through MET amplifications or mutations is present in 3-4% of stage IV non-squamous non-small cell lung cancers (NSCLC). High MET amplifications and exon 14 skipping mutations are associated with poor prognosis: new treatments are needed for these patients. Capmatinib is a highly selective, potent small-molecule MET inhibitor with antitumor activity in NSCLC in vitro and in vivo. ⋯ Expert opinion: In the GEOMETRY Mono-1 study, treatment with capmatinib resulted in high response rates in stage IV NSCLC with MET exon 14 skipping mutations, particularly in first line, supporting testing for this biomarker at the time of diagnosis. Durable responses have been reported and results in MET-amplified NSCLC are eagerly anticipated. In EGFR-mutant NSCLC, notable responses have been observed in combination with an EGFR-tyrosine kinase inhibitor (TKI) in case of acquired resistance to EGFR-TKIs based on high MET amplification.
-
Expert Rev Anticancer Ther · Aug 2019
ReviewSacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Introduction: Triple negative breast cancer (TNBC) is an aggressive breast cancer subtype associated with an increased risk of recurrence and cancer-related death. Unlike hormone receptor-positive or HER2-positive breast cancers, there are limited targeted therapies available to treat TNBC and cytotoxic chemotherapy remains the mainstay of treatment. Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate targeting Trop-2 expressing cells and selectively delivering SN-38, an active metabolite of irinotecan. ⋯ A confirmatory Phase III randomized clinical trial is ongoing. Sacituzumab govitecan has a manageable side effect profile, with the most common adverse events being nausea, neutropenia, and diarrhea. The activity of sacituzumab govitecan likely extends beyond TNBC with promising early efficacy data in many other epithelial cancers, including hormone receptor-positive breast cancer.
-
Expert Rev Anticancer Ther · Jul 2019
ReviewAn update on advanced dual-energy CT for head and neck cancer imaging.
Introduction: Dual-energy-computed tomography (DECT) is an advanced form of computed tomography (CT) that enables spectral tissue characterization beyond what is possible with conventional CT scans. DECT can improve non-invasive diagnostic evaluation of the neck, especially for the evaluation of head and neck cancer. Areas covered: This article is a review of current applications of DECT for the evaluation of head and neck cancer, focusing largely on squamous cell carcinoma (HNSCC). ⋯ This will be followed by a review of different DECT applications in diagnostic imaging and radiation oncology, practical and workflow considerations, and various emerging advanced applications for tumor analysis, including the use of DECT datasets for radiomics and machine learning applications. Expert opinion: Using a multi-parametric approach, different DECT reconstructions can be used to improve diagnostic evaluation and surveillance of head and neck cancer, including improving visibility of HNSCC, determination of tumor boundaries and extent, and invasion of critical organs such as the thyroid cartilage. In the future, the large amount of quantitative information on DECT scans may be leveraged for improving radiomic and machine learning models for tumor characterization.
-
Expert Rev Anticancer Ther · May 2019
ReviewOncologic therapies associated with cardiac toxicities: how to minimize the risks.
Recent breakthroughs in cancer treatment has improved the prospects and life expectancy of cancer patients. Therefore, risk of cardiotoxicity induced by oncologic therapies has become an important determinant of patient's survival and quality of life, independently of the oncologic prognosis. Areas covered: This paper provides an overview of the proposed strategies to mitigate the risk of cardiotoxicity. ⋯ Expert opinion: The most effective approach to minimize cardiotoxicity is early identification and early onset of a prophylactic treatment. However, the current standard of cardiac monitor identifies cardiotoxicity only when a functional impairment has already occurred, precluding any chance of effective prevention. The use of troponins to identify subclinical cardiotoxicity, and early treatment with ACE-inhibitors to prevent cardiac dysfunction and cardiac events have recently emerged, and appear to be an effective tool against this complication.